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The progress in research on molecular basis of on-
cogenesis has led to the unprecedented development of 
new anticancer treatment methods. Traditional cytotoxic 
drugs are increasingly being replaced by targeted thera-
pies, that affect molecular or immunologic mechanisms 
in cancer. Many of these drugs are of biological origin, 
and their active substances include polypeptides, glyco-
proteins, proteins, or nucleic acids, produced by living 
organisms or derived with the use of genetic manipula-
tions. These agents often require the use of advanced, 
specific diagnostic methods (companion diagnostics). 
Naturally, these highly specialised and “new-quality” 
therapies are very expensive (some prices at the time of 
marketing authorisation can reach hundreds of thousands 
of euros per year), that limits their availability. One of the 
ways to significantly reduce high costs is to replace the 
original biological drugs with their cheaper counterparts 
— biosimilars. In recent years, more than 20 biopharma-
ceuticals have been authorised in the European Union, 
including erythropoiesis or leukopenia stimulants, growth 
factors, ovulation stimulants, antibodies used in rheuma-
toid arthritis, and insulins. Up to now, among these newly 
registered biosimilars there were virtually no biological 
anticancer agents because their original prototypes were 
launched slightly later and are still covered by patent pro-
tection. However, in the coming years patent protection 
for the entire group of biological anticancer drugs expires 
(mainly monoclonal antibodies), that will undoubtedly 
result in their broad replacement with biosimilar drugs. 
Introduction of biosimilars raises hopes, but also some 
fears; these concern primarily the potential differences 
between original and reproductive biological drugs and 
the related questions regarding their effectiveness and 
safety. Indeed, while reproductive synthetic drugs are the 
same chemical molecules, a biosimilar, due to the complex 
biotechnological process of its production, cannot be 
considered to be an identical copy of its prototype. This 
situation is noticed by drug registration agencies; unlike 
synthetic reproductive medicine, registration of a repro-
ductive biological drug is subject to a number of additional 
requirements, including a clinical trial that confirms its 
reproducibility with the original, or prolonged period of 
safety monitoring (pharmacovigilance). Nevertheless, 
even meeting all these additional requirements does not 
allow unambiguous settlement of the aforementioned 
doubts. Examples of such dilemmas include exchange 
of original and biosimilar medicines, replacement of 
one biological drug for another during therapy, and the 
right to dispense by pharmacy a biosimilar instead of the 
original drug. In the European Union countries regula-
tions in this field are not the competence of the European 
Medicines Agency (EMA), but rather of member states’ 
institutions. In some countries, it is regulated on a legal 
basis, but in the majority, there is still space for different 
interpretations. Practitioners and pharmacists should not 
be faced with a situation in which they will have to resolve 
these problems themselves in their daily practice. Experts 
from the European Society for Clinical Oncology (ESMO) 
highlight that the physician should make a decision on the 
possible replacement of a biological drug due to his/her 
responsibility regarding monitoring a course of treatment. 
Recognising the importance of oncological biosimi-
lars the ESMO decided to publish a position statement 
in this matter. It is worthy to note that this document 
was signed by all members of the ESMO Management 
Board. We tried to objectively and sustainably present 
the opportunities that biosimilars provide in oncology 
but also highlight conditions that would enhance the 
safety of their use. This article is addressed to a wide 
range of professionals: physicians, pharmacists, drug 
manufacturers, national payers, and private insur-
ers. To facilitate access to this article, we published 
it in a web-based journal with open access ESMO 
Open — Cancer Horizons. The interest exceeded our 
expectations; within the first two months the number of 
downloads exceeded 6500. We hope that the publication 
of this article in Polish version will allow our community 
to become more familiar with this important topic.
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